Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101

The patent would provide protection of the commercial solid form of SCO-101 until at least 2042.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has received a favorable patentability opinion from the European Patent Office (EPO) on an international patent application aiming to further enhance the patent protection of Scandion’s lead compound SCO-101.

If granted, the patent will prolong the potential commercial exclusivity period for SCO-101. This could also allow Scandion to expand the development of SCO-101 into new indications and drug combinations, potentially making a future treatment available to more patients.

The international patent application relates to solid crystal forms of SCO-101. If granted, this Composition of Matter patent is envisaged to provide protection of the commercial solid form of SCO-101 until its expiry in 2042 or later.

“We are encouraged by the opinion from the EPO. If the patent is granted it could allow us to contemplate expanding the development of SCO-101 into new indications. In this way we could potentially help more of the patients who so desperately need new and improved cancer treatments”, says Francois Martelet, CEO of Scandion.

For further information please contact:

Johnny Stilou, CFO

Phone: +45 2960 3532

E-mail: jos@scandiononcology.com

The information was provided by the contact person above for publication on January 19, 2023, at 13.00 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.